clene inc - CLNN
CLNN
Close Chg Chg %
3.85 -0.23 -5.97%
Pre-Market
3.62
-0.23 (5.97%)
Volume: 252.78K
Last Updated:
Sep 8, 2026, 4:00 PM EDT
Company Overview: clene inc - CLNN
CLNN Key Data
| Open $3.82 | Day Range 3.60 - 3.82 |
| 52 Week Range 3.60 - 13.50 | Market Cap $49.47M |
| Shares Outstanding 12.85M | Public Float 10.59M |
| Beta 0.95 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.51 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 107.54K |
CLNN Performance
| 1 Week | -5.97% | ||
| 1 Month | -31.44% | ||
| 3 Months | -38.01% | ||
| 1 Year | -37.59% | ||
| 5 Years | -97.60% |
CLNN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
About clene inc - CLNN
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.
CLNN At a Glance
Clene, Inc.
6550 South Millrock Drive
Salt Lake City, Utah 84121
| Phone | 1-801-676-9695 | Revenue | 200.00K | |
| Industry | Pharmaceuticals: Major | Net Income | -26,173,000.00 | |
| Sector | Health Technology | Employees | 79 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CLNN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 289.359 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.444 |
| Enterprise Value to Sales | 371.779 |
| Total Debt to Enterprise Value | 0.291 |
CLNN Efficiency
| Revenue/Employee | 2,531.646 |
| Income Per Employee | -331,303.797 |
| Receivables Turnover | 0.339 |
| Total Asset Turnover | 0.009 |
CLNN Liquidity
| Current Ratio | 0.833 |
| Quick Ratio | 0.83 |
| Cash Ratio | 0.482 |
CLNN Profitability
| Gross Margin | -669.00 |
| Operating Margin | -11,541.50 |
| Pretax Margin | -13,086.50 |
| Net Margin | -13,086.50 |
| Return on Assets | -115.127 |
| Return on Equity | N/A |
| Return on Total Capital | -641.338 |
| Return on Invested Capital | -528.747 |
CLNN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 531.071 |
| Total Debt to Total Assets | 119.536 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 411.443 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Clene Inc - CLNN
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 473.00K | 654.00K | 342.00K | 200.00K | |
Sales Growth
| -34.58% | +38.27% | -47.71% | -41.52% | |
Cost of Goods Sold (COGS) incl D&A
| 1.43M | 1.83M | 1.72M | 1.54M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 1.41M | 1.71M | 1.65M | 1.50M | |
Depreciation
| 1.41M | 1.71M | 1.65M | 1.50M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +20.61% | +27.34% | -6.08% | -10.32% | |
Gross Income
| (961.00K) | (1.17M) | (1.37M) | (1.34M) | |
Gross Income Growth
| -106.22% | -21.96% | -17.15% | +2.55% | |
Gross Profit Margin
| -203.17% | -179.20% | -401.46% | -669.00% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 47.45M | 39.37M | 31.72M | 21.75M | |
Research & Development
| 31.13M | 25.22M | 18.68M | 12.66M | |
Other SG&A
| 16.32M | 14.15M | 13.04M | 9.09M | |
SGA Growth
| -4.17% | -17.03% | -19.43% | -31.45% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (21.53M) | 5.81M | 3.11M | 631.00K | |
EBIT after Unusual Expense
| (26.88M) | (46.35M) | (36.20M) | (23.71M) | |
Non Operating Income/Expense
| 257.00K | 1.40M | 864.00K | 223.00K | |
Non-Operating Interest Income
| - | 1.39M | 865.00K | 223.00K | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 3.30M | 4.56M | 4.06M | 2.68M | |
Interest Expense Growth
| +278.85% | +38.29% | -10.84% | -34.01% | |
Gross Interest Expense
| 3.30M | 4.56M | 4.06M | 2.68M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (29.92M) | (49.50M) | (39.40M) | (26.17M) | |
Pretax Income Growth
| -194.24% | -65.47% | +20.41% | +33.57% | |
Pretax Margin
| -6,325.16% | -7,569.42% | -11,520.47% | -13,086.50% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (29.92M) | (49.50M) | (39.40M) | (26.17M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (29.92M) | (49.50M) | (39.40M) | (26.17M) | |
Net Income Growth
| -207.17% | -65.47% | +20.41% | +33.57% | |
Net Margin Growth
| -6,325.16% | -7,569.42% | -11,520.47% | -13,086.50% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (29.92M) | (49.50M) | (39.40M) | (26.17M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (29.92M) | (49.50M) | (39.40M) | (26.17M) | |
EPS (Basic)
| -9.1766 | -9.4348 | -5.6657 | -2.6548 | |
EPS (Basic) Growth
| -189.99% | -2.81% | +39.95% | +53.14% | |
Basic Shares Outstanding
| 3.26M | 5.25M | 6.95M | 9.86M | |
EPS (Diluted)
| -9.1766 | -9.4348 | -5.6657 | -2.6548 | |
EPS (Diluted) Growth
| -189.99% | -2.81% | +39.95% | +53.14% | |
Diluted Shares Outstanding
| 3.26M | 5.25M | 6.95M | 9.86M | |
EBITDA
| (47.00M) | (38.84M) | (31.45M) | (21.59M) | |
EBITDA Growth
| +3.88% | +17.37% | +19.02% | +31.35% | |
EBITDA Margin
| -9,936.79% | -5,938.07% | -9,195.32% | -10,794.00% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 32.20 | |
| Number of Ratings | 5 | Current Quarters Estimate | -0.454 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | -2.574 | |
| Last Quarter’s Earnings | -1.08 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -2.65 | Next Fiscal Year Estimate | -1.496 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 5 | 5 | 5 |
| Mean Estimate | -0.45 | -0.43 | -2.57 | -1.50 |
| High Estimates | -0.41 | -0.35 | -2.46 | -0.37 |
| Low Estimate | -0.49 | -0.53 | -2.78 | -3.46 |
| Coefficient of Variance | -7.40 | -15.21 | -4.72 | -78.21 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 5 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Clene Inc - CLNN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Clene Inc - CLNN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Aug 17, 2026 | Reed N. Wilcox Director | 3,514 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 17, 2026 | David Jeffrey Matlin Director | 6,230 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 17, 2026 | Jonathon T. Gay Director | 3,794 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 17, 2026 | Alison H. Mosca Director | 4,872 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 17, 2026 | Arjun M. Desai Director | 3,674 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 17, 2026 | Shalom Jacobovitz Director | 4,752 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 17, 2026 | Vallerie V. Mclaughlin Director | 3,514 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 17, 2026 | Matthew Kiernan Director | 3,195 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 16, 2026 | Morgan R. Brown Chief Financial Officer | 15,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 16, 2026 | Mark G. Mortenson Chief Science Officer | 45,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 16, 2026 | Robert Dee Etherington President & CEO; Director | 65,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | David Jeffrey Matlin Director | 40,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | David Jeffrey Matlin Director | 93,333 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 1, 2026 | Chidozie Kermichael Ugwumba | 787,728 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.95 per share | 4,686,981.60 |
| Jan 1, 2026 | Chidozie Kermichael Ugwumba | 783,590 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.03 per share | 4,725,047.70 |